Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness of switching to the study drugs GS-3242 combined with Lenacapavir LEN compared to continuing the standard treatment Biktarvy bictegraviremtricitabinetenofovir alafenamide, BFTAF in adults with HIV-1 infection who are virologically suppressed. This Phase 2 randomized study aims to assess the safety and efficacy of an injectable regimen of GS-3242 plus LEN versus oral BFTAF in different treatment groups over distinct time points, with Part A focusing on Week 35 and Part B on Week 26. Participants are randomly assigned to receive either oral loading doses of GS-3242 and LEN tablets followed by intramuscular IM injections of these drugs for up to 52 weeks, or to continue daily oral BFTAF for the same duration. Different dosing regimens of GS-3242 and LEN are used across groups, with some groups receiving different IM doses. The study includes both randomized and non-randomized groups across the two parts. During the study, participants will be monitored for viral load, specifically HIV-1 RNA levels, using the US FDA Snapshot Algorithm at Weeks 26, 35, and 52, as well as CD4 cell counts. Safety is assessed by recording treatment-emergent adverse events throughout the study period. Drug concentrations are also measured at specific weeks to evaluate pharmacokinetics. The total participant involvement can last up to 52 weeks, with regular assessments to evaluate treatment efficacy and safety.
Actively Recruiting
Healthy Volunteer
Researchers are studying adults with significant abdominal fat to evaluate the effects of CBL-514 injection in reducing subcutaneous fat. This phase 2b randomized, placebo-controlled study aims to assess the efficacy, safety, and tolerability of multiple injections of CBL-514, compared to a saline placebo, with long-term re-treatment. The study focuses on adults with Grade 3 or Grade 4 abdominal fat as determined by both clinician and participant assessments. Participants will receive up to four subcutaneous treatments of either CBL-514 injection or a placebo solution, administered to the abdomen every three weeks. Each treatment consists of up to 120 mL of the assigned study drug. The trial uses a parallel design with random assignment to either the CBL-514 group or the placebo group to compare outcomes. Throughout the study, participants will undergo assessments to measure changes in abdominal fat at baseline and after treatment, including evaluations at 4 and 12 weeks following the final treatment. These assessments include clinician and patient-reported abdominal fat rating scales. Safety and tolerability will be monitored, with participants expected to follow study procedures and maintain a stable lifestyle. The total study duration spans from screening through final follow-up, ending in November 2027.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of FB102 in adults with severe to very severe alopecia areata, a condition causing significant hair loss. This randomized, double-blind, placebo-controlled Phase 1 study aims to better understand how FB102 works compared to a placebo in this patient group. Up to 32 participants will be randomly assigned in a 3 to 1 ratio to receive either FB102 or a matching placebo. Both treatments are given intravenously. The study will monitor participants over several weeks, assessing safety and changes in hair loss severity. Participants will be involved in the study for up to 36 weeks after their first dose. During this time, they will undergo regular evaluations including tracking treatment-related side effects and measuring changes in hair loss using the Severity of Alopecia Tool SALT score. Researchers will carefully monitor safety and treatment responses throughout the study.
Actively Recruiting
Researchers are evaluating the use of cemiplimab, a drug that helps the immune system target cancer cells by binding to a protein called PD-1, to treat early-stage Cutaneous Squamous Cell Carcinoma CSCC, a type of skin cancer. The study compares the effects of cemiplimab injected directly into the cancer lesion with the standard treatment of surgery. The main goals include assessing side effects and determining how well cemiplimab works compared to surgery. Participants will receive either intralesional injections of cemiplimab or undergo primary surgery, which could involve Mohs surgery or other methods ensuring complete margin assessment. The study design is randomized and parallel, meaning participants are assigned to one of these two groups. Treatments and evaluations occur according to a protocol, with follow-up to monitor response and safety. During the trial, participants will be monitored through various assessments including measuring event-free survival up to three years, evaluating complete response of the target lesion at week 13, and checking for adverse events over three years. Measurements of surgical and biopsy defect sizes will also be recorded. The study involves regular visits and follow-up evaluations to track treatment effects and safety throughout participation, which lasts up to the study completion date in 2030.